Verona Pharma plc Verona Pharma Plc To Announce Financial Results For Full Year Ended December 31, 2019 And Provide Corporate...
February 21 2020 - 2:00AM
UK Regulatory
TIDMVRP
LONDON, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP)
(Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical
company focused on respiratory diseases, announces that it will report
its audited financial results for the full year ended December 31, 2019
on Thursday, February 27, 2020 and host an investment community
conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss the full
year financial results and provide a corporate update.
To participate, please dial one of the following numbers and reference
conference ID 5394158:
-- 866-940-4574 for callers in the United States
-- 0800 028 8438 for callers in the United Kingdom
-- 0800 181 5287 for callers in Germany
A live webcast will be available on the Events and presentations link on
the Investors page of the Company's website,
https://www.globenewswire.com/Tracker?data=vzKXAOPJ7ycL4BPsNYPTJXrJoe5EwvCbtnJH9McgATjS45NhcW9XWPK7TG1H4DTbdnNXIBFF8x201OkOU-orgBubVHy46_bWOoryAuRacl0=
www.veronapharma.com, and an audio replay will be available there for 30
days.
About Verona Pharma
Verona Pharma is a clinical-stage biopharmaceutical company focused on
developing and commercializing innovative therapies for the treatment of
respiratory diseases with significant unmet medical needs. If
successfully developed and approved, Verona Pharma's product candidate,
ensifentrine, has the potential to be the first therapy for the
treatment of respiratory diseases that combines bronchodilator and
anti-inflammatory activities in one compound. Verona Pharma is currently
in Phase 2 development with three formulations of ensifentrine for the
treatment of COPD: nebulized, dry powder inhaler, and pressurized
metered-dose inhaler. Ensifentrine also has potential applications in
cystic fibrosis, asthma and other respiratory diseases. For more
information, please visit
https://www.globenewswire.com/Tracker?data=vzKXAOPJ7ycL4BPsNYPTJXjleuH4-XOMeUMkObg_VtsbZGIKeWCOdEAZam8e13JPfw7CLiteMNAXruNJ-lhJG2RQsewWzObkDopYIPfjejg=
www.veronapharma.com.
Verona Pharma plc Tel: +44 (0)20 3283 4200
--------------------------------------------------------- ---------------------------
David Zaccardelli, Chief Executive Officer info@veronapharma.com
--------------------------------------------------------- ---------------------------
David Moskowitz, VP Capital Markets Strategy & Investor
Relations (Investor Enquiries)
Victoria Stewart, Director of Communications (Media
Enquiries)
--------------------------------------------------------- ---------------------------
N+1 Singer Tel: +44 (0)20 3283 4200
(Nominated Adviser and UK Broker)
--------------------------------------------------------- ---------------------------
Aubrey Powell / George Tzimas / Iqra Amin (Corporate
Finance)
--------------------------------------------------------- ---------------------------
Tom Salvesen (Corporate Broking)
--------------------------------------------------------- ---------------------------
Optimum Strategic Communications Tel: +44 (0)20 950 9144
(European Media and Investor Enquiries) verona@optimumcomms.com
--------------------------------------------------------- ---------------------------
Mary Clark / Eva Haas / Hollie Vile
--------------------------------------------------------- ---------------------------
Argot Partners Tel: +1 212-600-1902
(US Investor Enquiries) verona@argotpartners.com
--------------------------------------------------------- ---------------------------
Stephanie Marks / Kimberly Minarovich / Michael Barron
--------------------------------------------------------- ---------------------------
(END) Dow Jones Newswires
February 21, 2020 02:00 ET (07:00 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024